Inhibrx Capital Expenditures Over Time
| INBX Stock | USD 15.63 0.18 1.17% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Inhibrx Performance and Inhibrx Correlation. Inhibrx |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibrx. If investors know Inhibrx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibrx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 119.39 | Revenue Per Share 0.117 | Quarterly Revenue Growth 2.333 | Return On Assets (0.57) | Return On Equity (20.31) |
The market value of Inhibrx is measured differently than its book value, which is the value of Inhibrx that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibrx's value that differs from its market value or its book value, called intrinsic value, which is Inhibrx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibrx's market value can be influenced by many factors that don't directly affect Inhibrx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibrx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inhibrx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibrx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Capital Expenditures Analysis
Compare Inhibrx and related stocks such as Crinetics Pharmaceuticals, Merus BV, and Lyell Immunopharma Capital Expenditures Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRNX | 190 K | 190 K | 190 K | 190 K | 190 K | 190 K | 190 K | 304 K | 1.1 M | 492 K | 186 K | 436 K | 1.7 M | 4.7 M | 4.9 M |
| MRUS | 114.6 K | 114.6 K | 114.6 K | 114.6 K | 190.9 K | 112.6 K | 521.6 K | 868.6 K | 4.2 M | 2.6 M | 1.3 M | 870 K | 7.6 M | 4 M | 2.2 M |
| LYEL | 16 M | 16 M | 16 M | 16 M | 16 M | 16 M | 16 M | 16 M | 16 M | 16 M | 51.5 M | 65.5 M | 24.3 M | 2.7 M | 2.6 M |
| KRON | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 2.9 M | 9.6 M | 4.3 M | 577 K | 679 K | 645 K |
| OPT | 0.0 | 39.9 K | 2.5 K | 111.1 K | 0.0 | 8.8 K | 2.4 K | 25.3 K | 8.8 K | 5 K | 17 K | 23.3 K | 32.6 K | 33.5 K | 31.8 K |
| MLYS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| ANEB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| CELC | 79 K | 79 K | 79 K | 79 K | 79 K | 79 K | 40.9 K | 239.8 K | 629.6 K | 380.2 K | 89.4 K | 81.9 K | 158.8 K | 97.6 K | 159.8 K |
| ELVN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 140 K | 461 K | 191 K | 612 K | 149 K | 244 K |
| GLUE | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 3.4 M | 9.7 M | 12.9 M | 19 M | 10.2 M |
| DSGN | 76 K | 76 K | 76 K | 76 K | 76 K | 76 K | 76 K | 76 K | 76 K | 76 K | 76 K | 1.5 M | 918 K | 256 K | 243.2 K |
| HOWL | 266 K | 266 K | 266 K | 266 K | 266 K | 266 K | 266 K | 266 K | 266 K | 266 K | 560 K | 498 K | 3.6 M | 769 K | 1.3 M |
| IKNA | 305 K | 305 K | 305 K | 305 K | 305 K | 305 K | 305 K | 305 K | 305 K | 316 K | 766 K | 1.8 M | 1.4 M | 414 K | 393.3 K |
| STOK | 113 K | 113 K | 113 K | 113 K | 113 K | 113 K | 113 K | 113 K | 935 K | 1.6 M | 1.1 M | 1.2 M | 4 M | 1.6 M | 1.7 M |
| PTGX | 299 K | 299 K | 299 K | 299 K | 299 K | 399 K | 379 K | 666 K | 486 K | 967 K | 471 K | 1.1 M | 795 K | 609 K | 678.9 K |
| LRMR | 58 K | 58 K | 58 K | 58 K | 58 K | 595 K | 660 K | 55 K | 108 K | 83 K | 62 K | 333 K | 100 K | 164 K | 177.4 K |
| VRDN | 106.9 K | 106.9 K | 106.9 K | 4.8 K | 266 K | 123 K | 3 K | 246 K | 445 K | 84 K | 42 K | 338 K | 797 K | 898 K | 942.9 K |
Inhibrx and related stocks such as Crinetics Pharmaceuticals, Merus BV, and Lyell Immunopharma Capital Expenditures description
Capital Expenditures are funds used by Inhibrx to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Inhibrx operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.My Equities
My Current Equities and Potential Positions
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.